Our data demonstrate that the expression levels of SRSF2, SFPQ or p54nrb impact on the sensitivity of ovarian cancer cells to PT-induced death and support the possibility that targeting alternative splicing, could also represent a promising therapeutic option to overcome PT resistance. Here, SFPQ is linked to ovarian carcinoma.